16/04/2026
Our Representation Layer Extends to a New Domain: 8 Therapies
Alphabiome extends its reference-free intelligence layer to a new domain, turning raw genetic signal into response prediction across three indications and 8 therapies.
See drug response
before the trial does.
Alphabiome transforms raw cohort sequencing and clinical outcomes into predictive patient stratification, novel biological signatures and interpretable mechanisms of response and non-response.
From cohort to answer.
Across seven human therapies, predictive performance exceeded AUC 0.85. Alphabiome outperformed every genomic and microbiome representation tested in the same evaluation framework and produced up to threefold responder enrichment compared with established clinical markers.
One representation. Multiple strategic uses.
Patient stratification
Clinical-trial enrichment
Drug rescue and repositioning
Mechanism discovery
Biomarker definition and deployment
Portfolio-level biological intelligence
Protected and difficult to reproduce.
Proprietary reference-free algorithms and accumulated token relationships.
Outcome-linked data and a global biological vocabulary.
Patented and patent-pending technology across 12 patent filings.
Bring us a biological dataset that existing AI cannot read.